Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
PLRX
PLRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest PLRX ETF News Today | Earnings, Events & Price Alerts
PLRX News
Pliant Therapeutics Shifts Focus to Oncology, Showcases Early PLN-101095 Data
3d ago
Yahoo Finance
Combination of Pliant Cancer Drug and Merck's Keytruda Enhances Treatment Responses in Challenging Tumors
Dec 04 2025
Benzinga
JP Morgan Lowers Pliant Therapeutics Rating to Underweight
Oct 10 2025
Benzinga
Biotech Stocks Surge in After-Hours Trading Following Trial News, Insider Purchases, and Conference Excitement
Sep 10 2025
NASDAQ.COM
Pliant ends development of idiopathic pulmonary fibrosis asset bexotegrast
Jun 27 2025
SeekingAlpha
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
May 01 2025
Newsfilter
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
Apr 25 2025
Globenewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
Apr 21 2025
Globenewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
Apr 17 2025
Globenewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
Mar 28 2025
PRnewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX
Mar 26 2025
Globenewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
Mar 23 2025
Globenewswire
HC Wainwright & Co. Reiterates Neutral on Pliant Therapeuticsto Neutral
Mar 18 2025
Benzinga
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
Mar 17 2025
Benzinga
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
Mar 15 2025
Globenewswire
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
Mar 13 2025
Newsfilter
Show More News
